BioSyent (RX) Scheduled to Post Quarterly Earnings on Thursday

BioSyent (CVE:RX) is scheduled to be releasing its earnings data after the market closes on Thursday, May 16th. Analysts expect BioSyent to post earnings of C$0.08 per share for the quarter.

BioSyent (CVE:RX) last announced its earnings results on Wednesday, March 13th. The company reported C$0.12 earnings per share for the quarter, missing analysts’ consensus estimates of C$0.17 by C($0.05). BioSyent had a return on equity of 18.97% and a net margin of 20.45%. The company had revenue of C$8.27 million during the quarter, compared to analyst estimates of C$8.80 million.

BioSyent Trading Up 0.9 %

BioSyent stock opened at C$8.59 on Friday. The firm has a 50-day moving average of C$8.60 and a 200-day moving average of C$8.54. BioSyent has a one year low of C$7.03 and a one year high of C$9.26. The company has a debt-to-equity ratio of 3.51, a current ratio of 6.48 and a quick ratio of 6.91. The company has a market cap of C$99.73 million, a price-to-earnings ratio of 16.21 and a beta of 0.93.

Insider Transactions at BioSyent

In other BioSyent news, insider BioSyent Inc. acquired 5,100 shares of BioSyent stock in a transaction dated Monday, April 29th. The stock was bought at an average cost of C$8.55 per share, for a total transaction of C$43,627.95. Company insiders own 38.45% of the company’s stock.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.